165 related articles for article (PubMed ID: 8912372)
1. Radiation dosimetry for 131I-mIBG therapy of neuroblastoma.
Flower MA; Fielding SL
Phys Med Biol; 1996 Oct; 41(10):1933-40. PubMed ID: 8912372
[TBL] [Abstract][Full Text] [Related]
2. Dosimetry of iodine 131 metaiodobenzylguanidine for treatment of resistant neuroblastoma: results of a UK study.
Fielding SL; Flower MA; Ackery D; Kemshead JT; Lashford LS; Lewis I
Eur J Nucl Med; 1991; 18(5):308-16. PubMed ID: 1936038
[TBL] [Abstract][Full Text] [Related]
3. Dosimetric considerations in 131I-MIBG therapy for neuroblastoma in children.
Bolster AA; Hilditch TE; Wheldon TE; Gaze MN; Barrett A
Br J Radiol; 1995 May; 68(809):481-90. PubMed ID: 7788233
[TBL] [Abstract][Full Text] [Related]
4. Iodine-131-metaiodobenzylguanidine dosimetry in cancer therapy: risk versus benefit.
Tristam M; Alaamer AS; Fleming JS; Lewington VJ; Zivanovic MA
J Nucl Med; 1996 Jun; 37(6):1058-63. PubMed ID: 8683301
[TBL] [Abstract][Full Text] [Related]
5. Phase I/II study of iodine 131 metaiodobenzylguanidine in chemoresistant neuroblastoma: a United Kingdom Children's Cancer Study Group investigation.
Lashford LS; Lewis IJ; Fielding SL; Flower MA; Meller S; Kemshead JT; Ackery D
J Clin Oncol; 1992 Dec; 10(12):1889-96. PubMed ID: 1453204
[TBL] [Abstract][Full Text] [Related]
6. Implications of the uptake of 131I-radiolabelled meta-iodobenzylguanidine (mIBG) for the targeted radiotherapy of neuroblastoma.
O'Donoghue JA; Wheldon TE; Babich JW; Moyes JS; Barrett A; Meller ST
Br J Radiol; 1991 May; 64(761):428-34. PubMed ID: 2036567
[TBL] [Abstract][Full Text] [Related]
7. The treatment of resistant neuroblastoma with 131I-mIBG: alternative methods of dose prescription.
Fielding SL; Flower MA; Ackery DM; Kemshead J; Lashford LS; Lewis IJ
Radiother Oncol; 1992 Sep; 25(1):73-6. PubMed ID: 1410594
[TBL] [Abstract][Full Text] [Related]
8. Treatment planning for 131I-mIBG radiotherapy of neural crest tumours using 124I-mIBG positron emission tomography.
Ott RJ; Tait D; Flower MA; Babich JW; Lambrecht RM
Br J Radiol; 1992 Sep; 65(777):787-91. PubMed ID: 1393416
[TBL] [Abstract][Full Text] [Related]
9. [131I]-metaiodobenzylguanidine in the treatment of metastatic neuroblastoma. Clinical, pharmacological and dosimetric aspects.
Klingebiel T; Treuner J; Ehninger G; Keller KD; Dopfer R; Feine U; Niethammer D
Cancer Chemother Pharmacol; 1989; 25(2):143-8. PubMed ID: 2598401
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and efficacy of 131I-meta-iodobenzylguanidine in two neuroblastoma xenografts.
Gaze MN; Hamilton TG; Mairs RJ
Br J Radiol; 1994 Jun; 67(798):573-8. PubMed ID: 8032811
[TBL] [Abstract][Full Text] [Related]
11. Toxicity from treatment of neuroblastoma with 131I-meta-iodobenzylguanidine.
Sisson JC; Hutchinson RJ; Carey JE; Shapiro B; Johnson JW; Mallette SA; Wieland DM
Eur J Nucl Med; 1988; 14(7-8):337-40. PubMed ID: 3181182
[TBL] [Abstract][Full Text] [Related]
12. Dosimetric considerations in 131I-MIBG therapy for neuroblastoma in children.
Bolster AA; Hilditch TE
Br J Radiol; 1995 Nov; 68(815):1263. PubMed ID: 8542240
[No Abstract] [Full Text] [Related]
13. 131I-meta-iodobenzylguanidine therapy in neuroblastoma spheroids of different sizes.
Gaze MN; Mairs RJ; Boyack SM; Wheldon TE; Barrett A
Br J Cancer; 1992 Dec; 66(6):1048-52. PubMed ID: 1457344
[TBL] [Abstract][Full Text] [Related]
14. The biodistribution and pharmacokinetics of meta-iodobenzylguanidine in childhood neuroblastoma.
Lashford LS; Moyes J; Ott R; Fielding S; Babich J; Mellors S; Gordon I; Evans K; Kemshead JT
Eur J Nucl Med; 1988; 13(11):574-7. PubMed ID: 3350034
[TBL] [Abstract][Full Text] [Related]
15. Enhanced tumour uptake and in vitro radiotoxicity of no-carrier-added [131I]meta-iodobenzylguanidine: implications for the targeted radiotherapy of neuroblastoma.
Mairs RJ; Russell J; Cunningham S; O'Donoghue JA; Gaze MN; Owens J; Vaidyanathan G; Zalutsky MR
Eur J Cancer; 1995; 31A(4):576-81. PubMed ID: 7576972
[TBL] [Abstract][Full Text] [Related]
16. A human neuroblastoma xenograft model for [131I]-metaiodobenzylguanidine (MIBG) biodistribution and targeted radiotherapy.
Rutgers M; Gubbels AA; Hoefnagel CA; Voûte PA; Smets LA
Prog Clin Biol Res; 1991; 366():471-8. PubMed ID: 2068162
[No Abstract] [Full Text] [Related]
17. The radiation dose to the urinary bladder in radio-iodine therapy.
Bolster AA; Hilditch TE
Phys Med Biol; 1996 Oct; 41(10):1993-2008. PubMed ID: 8912376
[TBL] [Abstract][Full Text] [Related]
18. Iodine-125-MIBG to treat neuroblastoma: preliminary report.
Sisson JC; Hutchinson RJ; Shapiro B; Zasadny KR; Normolle D; Wieland DM; Wahl RL; Singer DA; Mallette SA; Mudgett EE
J Nucl Med; 1990 Sep; 31(9):1479-85. PubMed ID: 2395016
[TBL] [Abstract][Full Text] [Related]
19. No-carrier-added iodine-131-MIBG: evaluation of a therapeutic preparation.
Mairs RJ; Cunningham SH; Russell J; Armour A; Owens J; McKellar K; Gaze MN
J Nucl Med; 1995 Jun; 36(6):1088-95. PubMed ID: 7769433
[TBL] [Abstract][Full Text] [Related]
20. Patient dosimetry after 131I-MIBG therapy for neuroblastoma and carcinoid tumours.
Monsieurs MA; Thierens HM; Vral A; Brans B; De Ridder L; Dierckx RA
Nucl Med Commun; 2001 Apr; 22(4):367-74. PubMed ID: 11338046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
